AbbVie(ABBV) - 2022 Q4 - Earnings Call Presentation

AbbVie Pipeline Update AbbVie R&D Pipeline Phase 1 Phase 2 Registrational / Phase 3 Submitted ■ CUG-252* (IL-2 Mutein) SLE ■ ABBV-154 (TNF-Steroid ADC) PMR ■ Rinvoq (JAK 1) GCA ■ Rinvoq (JAK 1) CD ■ CLF065* (GLP-2 agonist) IBD ■ ABBV-154 (TNF-Steroid ADC) CD ■ Skyrizi* (IL-23) UC ■ Epcoritamab* (CD3-CD20): R/R DLBCL ■ ABBV-151 (GARP+TGFb1) Solid Tumors ■ Rinvoq (JAK 1) Vitiligo ■ Imbruvica* (BTK) 1L FL ■ ABBV-951 (dopamine receptor) Advanced PD ■ ABBV-400 (cMet ADC) NSCLC ■ Rinvoq (JAK 1) SLE ■ Imbruvica* ( ...